Gadolinium-complexed Aβ-binding contrast agents for MRI diagnosis of Alzheimer's Disease

Neuropeptides. 2015 Oct:53:63-70. doi: 10.1016/j.npep.2015.07.001. Epub 2015 Jul 20.

Abstract

MRI contrast agents, containing peptide sequences that bind β-amyloid and gadolinium ions ligated to DOTA have been synthesized for evaluation in early diagnosis of Alzheimer's Disease in transgenic mice models. A number of brain penetration modifications were incorporated and sufficient amounts of contrast agent in the brain were achieved only by addition of a cationic cell penetration sequence along with the use of microparticle assisted ultrasound activation. In the T1 mode of a MRI scan, the peptide (R2) illuminated areas of brain rich in amyloid plaques.

Keywords: Alzheimer's; Contrast; MRI; Transgenic; β-Amyloid.

MeSH terms

  • Adult
  • Alzheimer Disease / diagnosis*
  • Alzheimer Disease / diagnostic imaging
  • Amyloid beta-Peptides* / chemistry
  • Amyloid beta-Peptides* / pharmacokinetics
  • Animals
  • Biosensing Techniques
  • Brain / pathology
  • Contrast Media* / pharmacokinetics
  • Gadolinium* / pharmacokinetics
  • Humans
  • Magnetic Resonance Imaging / methods*
  • Mice
  • Mice, Transgenic
  • Peptide Fragments / chemistry
  • Plaque, Amyloid / pathology
  • Positron-Emission Tomography
  • Radioisotopes
  • Tissue Distribution
  • Young Adult

Substances

  • Amyloid beta-Peptides
  • Contrast Media
  • Peptide Fragments
  • Radioisotopes
  • amyloid beta-protein (1-40)
  • amyloid beta-protein (1-42)
  • Gadolinium